Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with Gp120-depleted, inactivated HIV-1 in incomplete freund's adjuvant (REMUNE) in HIV-1-seropositive subjects

Journal of Human Virology

Volumn 1, Issue 2, 1998, Pages 77-81

  Moss, Ronald B ^a   Li, Li ^a   Giermakowska, Wieslawa K ^a   Lanza, Paola ^a   Turner, John L ^b   Wallace, Mark R ^c   Jensen, Fred C ^a   Richieri, Steven P ^a   Daigle, Anne E ^a   Theofan, Georgia ^a   Carlo, Dennis J ^a  

^a Orchestra Therapeutics Inc   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Space and Naval Warfare Systems Center Pacific   (United States)

Author keywords

HIV 1 Immunogen; Lymphocyte proliferation; RANTES; REMUNE; Tumor necrosis factor

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOSYNTHESIS; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MULTIMODALITY CANCER THERAPY; VACCINATION;

AIDS VACCINES; ANTI-HIV AGENTS; COHORT STUDIES; COMBINED MODALITY THERAPY; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION SCHEDULE; LYMPHOCYTE ACTIVATION; RANTES; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 0031598679     PISSN: 10909508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Moss ML, Jin S-L C, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour necrosis factor-α. Nature 1997;385:733-736.
2. Poli G, Kinter A, Justement JS, et al. Tumor necrosis factor a functions in an autocrine manner in the induction of human immunodeficiency virus expression, Proc Natl Acad Sci USA 1990;87:782-785.
3. Matsuyama T, Hamamoto Y, Soma G-I, Mizuno D, Yamamoto N, Kobayashi N. Cytocidal effect of Tumor necrosis factor on cells chronically infected with human immunodeficiency virus (HIV): enhancement of HIV replication. J Virology 1989;63:2405-2509.
4. Aukrust P, Liabakk N-B, Muller F, Lien E, Espevik T, Froland SS. Serum levels of tumor necrosis factor alpha (TNF-α) and soluble TNF receptors in human immunodeficiency virus type 1 infection: correlations to clinical, immunologie, and virologic parameters. J Infect Dis 1994; 169:420-424.
5. Rizzardi GP, Barcellini W, Tambussi G, et al. Plasma levels of soluble CD30, tumour necrosis factor (TNF)-α and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome. AIDS 1996;10:F45-50.
6. Bilello JA, Stellrecht K, Drusano GL, Stein DS. Soluble tumor necrosis factor-α receptor type II (sTNFαRII) correlates with human immunodeficiency virus (HIV) RNA copy number in HIV-infected patients. J Infect Dis 1996; 173:464-467.
7. Salazar-Gonzalez JF, Martinez-Maza O, Aziz N, et al. Relationship of plasma HIV-RNA levels and levels of TNF-α and immune activation products in HIV infection. Clin Immunol Immunopathol 1997;84:36-45.
8. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11:247-257.
9. Lahdevirta J, Maury CPJ, Teppo A-M, Repo H. Elevated levels of circulating cathectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:289-291.
10. Schnittman SM, Fox L. Preliminary evidence for partial restoration of immune function in HIV type 1 infection with potent antiviral therapies: clues for the Fourth Conference on Retroviruses and Opportunistic Diseases. AIDS Res Hum Retroviruses 1997;13:815-818.
11. Cocchi F, Devico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8 T cells. Science 1995;270:1811-1815.
12. Ferbas J, Plaeger S, Amini S, et al. [poster 91]. Presented at the Conference on Advances in AIDS Vaccine Development: Ninth Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Bethesda, MD, May 4-7, 1997.
13. Rosenberg E, Billingsley J, Kalams S, et al. [abstract 760]. Presented at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
14. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996;271:324-328.
15. Trauger RJ, Ferre F, Daigle AE, et al. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type-1 (HIV-1) Immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Infect Dis 1994;169:1256-1264.
16. Turner JL, Trauger RJ, Daigle AE, Carlo DJ. HIV-1 Immunogen induction of HIV-1-specific delayed-type hypersensitivity: results of a double-blind, adjuvant-controlled, dose-ranging trial. AIDS 1994;8:1429-1435.
17. Moss RB, Trauger RJ, Giermakowska WK, et al. Effect of immunization with an inactivated gp120-depleted HIV-1 Immunogen on β-chemokine and cytokine production in subjects with HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:343-350.
18. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor a and interleukin-1 stimulate the human deficiency virus enhancer by activation of the nuclear factor KB. Proc Natl Acad Sci USA 1989;86:2336-2340.
19. + T cell anergy. Clin Exp Immunol 1997;109:41-46.
20. Neoh LP, Akimoto H, Kaneko H, et al. The production of β chemokines induced by HIV-2 envelope glycoproteins. AIDS 1997;11:1062-1063.
21. Moss RB, Richieri SP, Ferre F, et al. HIV-1-specific functional immune measurements as markers of disease progression. J Biomed Sci 1997;4:127-31-